Detalhe da pesquisa
1.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
N Engl J Med
; 389(23): 2162-2174, 2023 Dec 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38055253
2.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Lancet
; 403(10421): 31-43, 2024 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048793
3.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lancet
; 403(10434): 1341-1350, 2024 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38521086
4.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
N Engl J Med
; 386(5): 437-448, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045221
5.
Survival with Cemiplimab in Recurrent Cervical Cancer.
N Engl J Med
; 386(6): 544-555, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35139273
6.
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Oncologist
; 29(1): 25-35, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523661
7.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med
; 385(20): 1856-1867, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34534429
8.
Real world data of niraparib in platinum sensitive relapsed ovarian cancer: A multicenter experience of the MITO group.
Gynecol Oncol
; 184: 24-30, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277918
9.
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Gynecol Oncol
; 183: 61-67, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38518529
10.
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
Future Oncol
; 2024 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38501262
11.
Best original research presented at the 24th European Congress on Gynaecological Oncology-Best of ESGO 2023.
Int J Gynecol Cancer
; 34(4): 610-618, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38088184
12.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Int J Gynecol Cancer
; 34(4): 550-558, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38129136
13.
Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives.
Curr Opin Obstet Gynecol
; 36(1): 9-17, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38170548
14.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(4): 392-402, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36878237
15.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 24(3): 286-296, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37052965
16.
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Gynecol Oncol
; 169: 27-33, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493574
17.
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial.
Gynecol Oncol
; 172: 72-77, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36965291
18.
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Gynecol Oncol
; 173: 98-105, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37105063
19.
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.
Gynecol Oncol
; 175: 182-189, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355448
20.
Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives.
Curr Oncol Rep
; 25(11): 1307-1326, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870697